European Pharmaceutical Review

AUGUST 24, 2022

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. A key aspect in removing many existing hurdles lies in the linker and conjugation of the two therapeutic modalities while maintaining the properties of the naked antibody.

Compounding 82

Compounding Pharmaceutical Companies Pharmaceutical Companies 82

The Checkup by Singlecare

MARCH 21, 2023

Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag. By employing therapeutic exercise, physical therapy aims to achieve optimal neuromuscular and skeletal function. RELATED: Belbuca side effects 2.

Dosage 52

Dosage Controlled Substances Labelling Packaging 52

pharmaphorum

DECEMBER 2, 2020

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The trial continued enrolment in a 1:1 ratio into the two combination arms: the investigational arm of U2 and the control arm of obinutuzumab plus chlorambucil.

FDA 52

FDA Chemotherapy 52